At the Metro Drug Coalition in Knoxville, they see addiction walk through the door every day. According to MDC’s Karen ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Ark is already conducting studies with this new class of pain medication, leveraging its strong infrastructure, experienced staff, and extensive access to patient populations. With strong community ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

As a result, the need for nonaddictive substances is more important than ever before. Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 ...